Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Medicinal chemistry Basics

7,440 views

Published on

Medicinal chemistry, Drug Discovery Introduction
From Braham Partick Book

Published in: Science
  • I am so pleased that I found you! I have suffered from Sleep Apnea for years. I have tried everything to fix the problem but nothing has worked. For the last years I have been trying to use a CPAP machine on and off but it is very difficult to sleep with. It's noisy and very uncomfortable. I had no idea there was a natural way to help me. I am so pleased that I found you! ♣♣♣ http://t.cn/AigiCT7Q
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Nothing short of a miracle! I'm writing on behalf of my husband to send you a BIG THANK YOU!! The improvement has been amazing. Peter's sleep apnea was a huge worry for both of us, and it left us both feeling tired and drowsy every morning. What you've discovered here is nothing short of a miracle. God bless you. ♣♣♣ https://bit.ly/37PhtTN
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here

Medicinal chemistry Basics

  1. 1. Medicinal Chemistry In medicinal chemistry, the chemist attempts to design and synthesize a medicine or a pharmaceutical agent which will benefit humanity. Such a compound could also be called a 'drug‘. Latin ars medicina, meaning the art of healing It involves: • Synthesis • Structure-Activity Relationships (SAR) • Receptor interactions • Absorption, distribution, metabolism, and excretion (ADME) Medicinal chemistry
  2. 2. 1. Chem. Rev., 2014, 114 (8), pp 4540–4563 Drug discovery Small molecules NCEs Inorganic molecules1 Organic molecules Large molecules (Proteins, oligosaccharides NTBP Medicinal chemistry2 Drug discovery
  3. 3. “Big Pharma” Drug Discovery in the 21st Century The Problem: The pharmaceutical industry is short of new drugs. In the 2nd part of the 20th century, about 50-60 new drugs (NCEs) were approved by the FDA every year. In contrast, in 2002, a historical low of 18 NCEs were approved (in 2001, 24 NCEs, in 2000, 27 NCEs, in 2003, 21 NCEs, 2011, 30 NCEs, 2012, 39 NCEs, 2013, 27 NCEs, 2014 , 41 NCEs + New Therapeutic Biological Product (NTBP) 2015, 15 NCEs + NTBP). Conversely, research costs for a new drug are estimated to be in the $1-1.5 Bi. range. Considering all high-profile failures in recent drug discovery, this figure is unlikely to drop substantially. Medicinal chemistry
  4. 4. In Search of New Leads….. The decline in the number of new drugs is based, among other reasons, on the current high therapeutic standard in many indications, focusing research on chronic diseases such as coronary heart, Alzheimer’s, arthritis, cancer, and AIDS, as well as the enhanced regulatory requirements for efficacy and safety of new drugs. A lead can be characterized as a compound that has some desirable biological activity, not extremely polar or lipophilic, and not contain toxic or reactive functional groups. Often, molecular weight (<350) and lipophilicity (log P < 3) are considered the most obvious characteristics of a drug-like lead. The lead should also have a series of congeners that modulate biological activity, indicating that further structural modification will improve selectivity and potency. Medicinal chemistry
  5. 5. New drugs from old poisons The reductionist approach to medicine began with the isolation of opium alkaloids O HO H N HO CH3 O O H N O CH3 O CH3 O CH3 O CH3O H N HO CH3 codeine heroin morphine Medicinal chemistry
  6. 6. Medicinal Chemistry Folklore Earliest medicines ~ 5100 years ago Chinese emperor Shen Nung - book of herbs, Pen Ts’ao Ch’ang Shan - contains alkaloids; used today in the treatment of malaria and for fevers Ma Huang - contains ephedrine; used as a heart stimulant and for asthma. Now used by body builders and endurance athletes because it quickly converts fat into energy and increases strength of muscle fibers. Modern therapeutics: Extract of foxglove plant, cited by Welsh physicians in 1250. Used to treat dropsy (congestive heart failure) in 1785 Contains digitoxin and digoxin; today called digitalis Medicinal chemistry
  7. 7. At least a quarter of all prescriptions dispensed in the US and UK contain, as active compounds, molecules derived from flowering plants. Other data show that 12 out of the top 25 highest earning drugs in 1995 were derived from natural products. The importance of plants as medicines in the developing world should also be acknowledged. Here, they are estimated to comprise 80% of the medication used in primary healthcare (Source: Houghton, P. J., "Roots of remedies: Plants, people and pharmaceuticals." Chem. Ind. 1999, 15). • Ethnographies show that humans are great botanical experimentors • Perhaps human brains, drugs and spices evolved together! Medicinal chemistry
  8. 8. Examples of Natural Products as Leads & Drugs Cardiac glycosides, morphine, quinine, salicylic acid, taxol, camptothecin, penicillin, cyclosporin A, warfarin, artemisine…. O HO RO N R = H: Morphine R = Me: Codeine (pain killer) HO H H OH H HO H H OH HH 17-ethynylestradiol norethindrone (the "Pill"; contraceptive) Clarithromycin (antibacterial) O O O OH OMeHO O O O OMe OH O HO N HO O N S O NH2 CO2H HH Ampicillin (antibiotic) N O O OH CO2H Clavulanic acid -lactamase inhibitor) Augmentin (antibiotic) N N O O O N HN N N H H N N O O O O O O N O OH N O N H Cyclosporine A 1 2 3 4 56 7 89 10 11 Medicinal chemistry
  9. 9. Current use of natural product extracts QuickTime™ and a TIFF (Uncompressed) decompressor are needed to see this picture. High-Pressure Accelerated Solvent Extractor System DCM & MeOH Extracts QuickTime™ and a TIFF (Uncompressed) decompressor are needed to see this picture. QuickTime™ and a TIFF (Uncompressed) decompressor are needed to see this picture. Parallel HPLC HT Solvent Concentrator Quic kTime™ and a Graphic s dec ompressor are needed to see this picture. Quic kTime™ and a Graphic s dec ompressor are needed to see this picture. Quic kTime™ and a Graphic s dec ompressor are needed to see this picture. Quic kTime™ and a Graphic s dec ompressor are needed to see this picture. Multiwell Plates For HTS Medicinal chemistry
  10. 10. Drug Discovery One way to “discover” drugs Medicinal chemistry
  11. 11. Serendipitous Drug Discovery • The use of nitrous oxide and ether as narcotic gases in surgery resulted from the observation that people who inhaled these chemicals [in parties] did not experience any pain after injury. • The vasodilatory activity of amyl nitrite and nitroglycerin was discovered by chemists who developed strong headaches after inhaling or ingesting minor amounts. • A wrong working hypothesis on chloral hydrate, which was supposed to degrade metabolically to narcotic chloroform, led to its application as a strong sedative (in reality, the metabolite trichloroethanol is the active form). Similarly, urethane was supposed to release ethanol but is a hypnotic by itself. • Acetylsalicylic acid was thought to be just a better tolerable prodrug of salicylic acid, but turned out to have a unique mechanism. • Phenolphthalein was considered as a useful dye for cheap wines; after a heroic self-experiment, a pharmacologist experienced its drastic diarrhoic activity. • Warfarin was used a rat poison. Medicinal chemistry
  12. 12. How should they respond to the challenges of biological networks? • 1970-1990 – clinical success driven by selectivity for single targets (e.g. h2 antagonists, AII inhibitors). Medchem is driven by isolated enzyme assays or analytical pharmacology. • 1990-2000 – as therapeutic targets become more challenging, high- throughput screening, fed by massively combinatorial chemistry, drives expectations upwards – BUT the same technology demands assay systems even less related to the constituted organism! • 2000- 2005 – unmet expectations drive a much more focused approach to screening but compounds are still, essentially, optimised against single reductionist assays. • 2005- present – increasing realisation that reductionist assays do not predict cell network responses – primary cell screening begins to gain ground.
  13. 13. Serendipitous Discovery of Librium without a Lead In 1955 Roche set out to prepare a series of benzheptoxdiazines as potential new tranquilizer drugs, but the actual structure was found to be that of a quinazoline 3-oxide. 2.4 N O N R2 R1 X Y 2.5 + -N N R1 O R2 X Y No active compounds were found, so the project was abandoned Medicinal chemistry
  14. 14. In 1957, during a lab cleanup, a vial containing what was thought to be the latter compound (X = 7-Cl, R1 = CH2NHCH3, R2 = C6H5) was sent for testing, and it was highly active. Further analysis showed that the actual structure of the compound was the benzodiazepine 4-oxide, Librium, presumably produced in an unexpected reaction of the corresponding chloromethyl quinazoline 3-oxide with methylamine. N N CH2Cl OCl N H N NHCH3 OCl CH2Cl CH3NH2 N CH2 N NHCH3 Cl Cl OH N N CH2NHCH3 OCl .. -+ - + - + .. 2.6 CH3NH2 N N Cl NHCH3 . HCl O chlordiazepoxide HCl 2.3 + - Librium Medicinal chemistry
  15. 15. Rational Drug Discovery • Nearly every modification of neurotransmitters dopamine, serotonin, histamine, or acetylcholine by classical medicinal chemistry led to a compound with modified activity and selectivity. • Steroid hormone modifications led to similar success stories. • Many enzyme inhibitors were developed from leads that mimic the transition state of the corresponding enzyme. Protease inhibitors started from cleavage-site peptides by converting the critical amide bond into another functionality. For example, aspartyl protease inhibitors should contain the amino acids at both sides of the cleavable peptide bond, and the latter bond needs to be replaced by a stable isostere that resembles the transition state. • In the 1980’s and 1990’s, computer modeling of enzyme-substrate complexes became a major driving force for rational drug discovery and the interpretation of SAR results. Medicinal chemistry
  16. 16. How should the medicinal chemist respond? • Historically – screen in a “black box” – empirical SAR but high relevance and “guaranteed efficacy” • Contemporary – screen target in isolation – “precision” SAR but relevance and efficacy unclear • The “compromise” – take secondary screening into the cellular context (still much scepticism about primary cellular screening!); really depends on the degree to which the cell assays reproduce the target disease • So how DO we blend the efficacy lessons of the past, underpinned by network pharmacology evidence, with modern screening and secondary assay technologies? • How much must we change our mindset? After all, we optimise activity and ADME/PK more or less in parallel these days – is an extra parallel target or two a quantum leap?
  17. 17. Lead optimisation – where (medchem) going gets tough! • Balance of activities – into the nearly-unknown; until more data are available from network biomarker and enzyme-occupancy studies, balanced potency is the best guess – very high multipotency may well not be required • Balance of physicochemical properties – tricky for MKIs where structural additivity tends to correlate with selectivity – however, deliberate choice of overlapping pharmacophores helps; non-oncology applications are more challenging • Balance of off-target activities – this issue is no different in principle to that for so-called “selective” kinase inhibitors, of which there are not many. Isolated enzyme assays are, at best, an approximate guide to undesirable intra-family activities. Monitoring cellular target/s activity against in vitro and in vivo toxicity readouts are essential in lead optimisation.
  18. 18. Why should drug discoverers bother about biological networks? • nearly all drugs can hit more than one effector target in an organism • not all “non-target” effectors are off-targets, metabolic systems or transporters • accumulated genomic/proteomic/analytical pharmacological knowledge confirm that several highly efficacious drugs exert their overall therapeutic effect through a network of effectors • the output of the network determines the drug profile (i.e. its good points and its bad points)
  19. 19. Structure-Activity Relationships (SARs) 1868 - Crum-Brown and Fraser Examined neuromuscular blocking effects of a variety of simple quaternary ammonium salts to determine if the quaternary amine in curare was the cause for its muscle paralytic properties. Conclusion: the physiological action is a function of chemical constitution Medicinal chemistry
  20. 20. Structurally specific drugs (most drugs): Act at specific sites (receptor or enzyme) Activity/potency susceptible to small changes in structure Structurally nonspecific drugs: No specific site of action Similar activities with varied structures (various gaseous anesthetics, sedatives, antiseptics) Medicinal chemistry
  21. 21. Example of SAR sulfa drugs 2.1 H2N SO2NHR Lead: sulfanilamide (R = H) Thousands of analogs synthesized From clinical trials, various analogs shown to possess three different activities: • Antimicrobial • Diuretic • Antidiabetic Medicinal chemistry
  22. 22. SAR General Structure of Antimicrobial Agents 2.32 NH2 R R = SO2NHR, SO3H • Groups must be para • Must be NH2 (or converted to NH2 in vivo) • Replacement of benzene ring or added substituents decreases or abolishes activity • R can be , , , (but potency is reduced) • R = SO2NR2 gives inactive compounds NH2SO2 NH2SO O CNH2 O C R Medicinal chemistry
  23. 23. Rational Drug Discovery - Piroxicam • It took Pfizer about 18 years to develop the anti-inflammatory drug piroxicam, which was launched in 1980 during the “golden age of rational drug discovery”. • The starting point for the development was chemistry-driven, ie. to identify acidic, but not carboxylic acid-containing (salicylic acid) structurally novel compounds. • Measurement of a physical property (pKa) as well as serum half-life in dogs was the guide for the synthesis program. • Several generations of leads were refined and ultimately led to a successful structure with an acceptable safety and activity profile: O O Ar S O O Ar O N O O R NHArO S N O O R NHArO O S N O R O OH O NHAr Medicinal chemistry
  24. 24. Bioisosterism Bioisosteres - substituents or groups with chemical or physical similarities that produce similar biological properties. Can attenuate toxicity, modify activity of lead, and/or alter pharmacokinetics of lead. Medicinal chemistry
  25. 25. Table 2.2 1. Univalent atoms and groups a. CH3 NH2 OH F Cl b. Cl PH2 SH c. Br i-Pr d. I t-Bu 2. Bivalent atoms and groups a. NHCH2 O S Se b. COCH2R CONHR CO2R COSR 3. Trivalent atoms and groups a. CH N b. P As 4. Tetravalent atoms Ca. Si b. 5. Ring equivalents a. CH S (e.g., benzene, thiophene) b. CH N (e.g., benzene, pyridine) c. O S CH2 NH (e.g., tetrahydrofuran, tetrahydrothiophene, cyclopentane, pyrrolidine) CH C N P Classical Isosteres Medicinal chemistry
  26. 26. Do not have the same number of atoms and do not fit steric and electronic rules of classical isosteres, but have similar biological activity. Non-Classical Isosteres 1. Carbonyl group 2. Carboxylic acid group 3. Amide group O NC C CN O SC O S O O S N O R CN O CH CN NOH C NOCH3 C O C OH O S O N H R O S O OH O P NH2 OH O P OEt OH O C NH CN N O OH O O OH N NN N H F OH F N S OH O N OH N N OH CH3 NH X O O N N OH N N N OH N N N N OH O N H S Ar O O S O N H S Ar O OO N H O N H S Ar O O OH O C NH2 O C HN S C NH2 O C CH2 O C HN NH2 O C HN O O C OR O S HN O- CH2 OH N NH2 CH3 N NH2 H2 C Medicinal chemistry
  27. 27. 4. Ester group 5. Hydroxyl group 6. Catechol 7. Halogen 8. Thioether 9. Thiourea O C OR N S N R' N O N R' N O N R' N N O OR N N S OR N N N OR R' N N N N R' NO OR S O O- NRR' O C N F R OH NHCR O NHSO2R CH2OH NHCNH2 O NHCN CH(CN)2 HO HO H N N X HO O N HO O X = O, NR HO S HN O X CF3 CN N(CN) 2 C(CN)3 S O NC CN N CN —NH N NH2NH2 —NH NH2—NH NO2 N NH2 SO2NH2 CN S Medicinal chemistry
  28. 28. Examples of Bioisosteric Analogues NH N (CH2)3—X— R O CX = or CH CN N CH3 O X CH3O O Cl N CH3 O OH Y N Z N N H X = OH (indomethacin) = NHOH = Y = CH3 O Z = Cl Y = F Z = SCH 3 (sulindac) N N H H N N (n = 1, 2) (n = 1) X = NH, O, CH2 Y = N (CH3)2 (n = 2) R — X — (CH 2)n — Y Neuroleptics (antipsychotics) Anti-inflammatory agents Antihistamines Diphenhydramine (Benadryl) Fexofenadine (Allegra) Ph O Ph N NHO Ph Ph OH CO2H Medicinal chemistry
  29. 29. Changes resulting from bioisosteric replacements: Size, shape, electronic distribution, lipid solubility, water solubility, pKa, chemical reactivity, hydrogen bonding Effects of bioisosteric replacement: 1. Structural (size, shape, H-bonding are important) 2. Receptor interactions (all but lipid/H2O solubility are important) 3. Pharmacokinetics (lipophilicity, hydrophilicity, pKa, H- bonding are important) 4. Metabolism (chemical reactivity is important) Bioisosteric replacements allow you to tinker with whichever parameters are necessary to increase potency or reduce toxicity. Medicinal chemistry
  30. 30. Bioisosterism allows modification of physicochemical parameters Multiple alterations may be necessary: If a bioisosteric modification for receptor binding decreases lipophilicity, you may have to modify a different part of the molecule with a lipophilic group. Where on the molecule do you go to make the modification? The auxophoric groups that do not interfere with binding. Medicinal chemistry
  31. 31. Rational Drug Discovery - From Hit to Lead - Li, X.; Chu, S.; Feher, V. A.; Khalili, M.; Nie, Z.; Margosiak, S.; Nikulin, V.; Levin, J.; Sprankle, K. G.; Tedder, M. E.; Almassy, R.; Appelt, K.; Yager, K. M., "Structure- based design, synthesis, and antimicrobial activity of indazole-derived SAH/MTA nucleosidase inhibitors." J. Med. Chem. 2003, 46, 5663-5673. -Background: “S-adenosyl homocysteine/methylthioadenosine (SAH/ MTA) nucleosidase presents a potentially useful target: -First, its active site is similarly highly conserved across bacterial species, while differing from that of the related mammalian proteins. -Second, SAH/MTA nucleosidase participates in the synthesis of the quorum sensing autoinducer AI-2, which in turn stimulates expression of virulence factors. Consequently, inhibiting SAH/MTA nucleosidase should attenuate bacterial virulence. -Third, and most importantly, such inhibition should kill bacteria because accumulation of SAH and MTA inhibits certain essential methyltransferase reactions and thereby impedes recycling of adenine and methionine, which are necessary for DNA and protein synthesis, respectively. Medicinal chemistry
  32. 32. N NN N NH2 O OH OH S R R = MTA/SAH Nucleosidase (MTAN) O2C NH3 + S-Adenosylhomocysteine (SAH) H3CR = Methylthioadenosine (MTA) O OH OH S R OH N NN N H NH2 Adenine R = O2C NH3 + S-Ribosylhomocysteine (SRH) H3CR = Methylthioribose (MTR) Rational Drug Discovery - From Hit to Lead Medicinal chemistry
  33. 33. Rational Drug Discovery - From Hit to Lead -SAR: In Silico Lead Identification. “Selection of compounds for screening in the SAH/MTA nucleosidase activity assay began by filtering a virtual library of 390 000 commercially available compounds to approximately 2000 satisfying the following criteria: (i) possessing three pharmacophoric features identified from inspection of homology model- substrate complexes, (ii) having molecular volumes less than that of the homology model binding pocket, and (iii) conforming to Lipinski guidelines (i.e., molecular weight < 500, -2.0 < ClogP < 5.0). The resulting data set was clustered for 2D fingerprint diversity and a representative selection of 1288 compounds identified using SELECTOR (Tripos, Inc.). X-ray structural determination of lead compounds cocrystallized with SAH/MTA nucleosidase derived from Escherichia coli and other pathogenic species revealed the mode of inhibitor binding within the active site. These co-structures provided the structural information for design of individual compounds and focused libraries.” Use of 5-aminoindazole as the core scaffold provided a structure-guided series of low nanomolar inhibitors with broad-spectrum antimicrobial activity. The implementation of structure-based methodologies provided a 6000-fold increase in potency over a short timeline (several months) and an economy of synthesized compounds. Medicinal chemistry
  34. 34. “Me Too” Compounds Copying existing drugs with only minor chemical variations is usually referred to as “me too” research. Interestingly, sometimes these close analogs demonstrate major (usually unexpected) advantages, like the bioavailable, broad-spectrum lactamase-resistant penicillins, polar H1 antihistamins without sedative side effects, statins, or PDE5 inhibitors.
  35. 35.  Ionisation  Lipophilicity  Hydrogen bonding  Molecular size  Rotatable bonds  Bulk physical properties  Lipinski Rule of Five  The Drug Design Conundrum
  36. 36. Medicinal chemistry36 Thank you all

×